文献速递炎症性肠病

亚洲急性重症溃疡性结肠炎患者结肠切除风险低于澳新地区

Acute Severe Ulcerative Colitis Patients From Asia Have Lower Colectomy Risk Than Patients From Australasia.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-10-30

这项多国多中心回顾性队列研究纳入2015至2020年861例符合Truelove和Witts标准的急性重症溃疡性结肠炎住院患者,比较亚洲与澳大利亚新西兰(ANZ)患者特征与结局。亚洲患者内镜更重、病变更广泛,但皮质类固醇失败率、住院及1年结肠切除率、12个月内再入院率均显著低于ANZ。

要点

  • 亚洲ASUC患者内镜更重、病变更广泛,但皮质类固醇失败率更低。
  • 亚洲患者住院结肠切除率2.8% vs ANZ 10.9%,1年结肠切除率4.7% vs 22.5%。
  • 亚洲患者出院时更少使用皮质类固醇、硫嘌呤或高级治疗,但随访中更多依赖皮质类固醇。

核心结论

  • 亚洲ASUC患者特征与ANZ显著不同,尽管内镜更重、病变更广泛,但皮质类固醇反应性更好,结肠切除率显著更低,对高级治疗需求更少。

研究设计与样本

  • 多国多中心回顾性队列研究,纳入2015年1月至2020年12月4个亚洲国家14家医院和9家ANZ医院连续住院的符合Truelove和Witts标准的ASUC患者,共861例(亚洲430例,ANZ 431例)。

主要发现

  • 亚洲队列有IBD家族史比例更低(P < .001),诊断时病变更广泛(P < .001),内镜严重度更差(P < .001)。
  • 入院时亚洲患者正在使用皮质类固醇、硫嘌呤和生物制剂者显著更少,既往生物制剂暴露更少(P < .005)。
  • 亚洲队列皮质类固醇失败率21.5% vs 57.2%(P < .001),住院结肠切除率2.8% vs 10.9%(P < .001),1年结肠切除率4.7% vs 22.5%(P < .001),12个月内ASUC再入院率9.3% vs 16.1%(P < .001),经倾向评分匹配队列验证。
  • 出院时更多亚洲患者使用5-氨基水杨酸(P = .014),更少使用皮质类固醇(P = .049)、硫嘌呤(P < .001)或高级治疗(P < .001),但随访中更多保持皮质类固醇依赖(P < .029)。

临床怎么用

  • 亚洲ASUC患者尽管内镜表现更重,但皮质类固醇反应性更好、结肠切除风险更低,临床决策时应考虑地区差异。
  • 亚洲患者出院时更少使用高级治疗但更多皮质类固醇依赖,需关注随访中的激素依赖管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The incidence of ulcerative colitis (UC) and acute severe UC (ASUC) is rapidly increasing in Asia but remains lower than Australia and New Zealand (ANZ). Studies in Asian countries report differences in UC characteristics and lower colectomy risk. We aimed to compare ASUC characteristics and outcomes in Asia and ANZ. METHODS: This was a multinational, multicenter retrospective cohort study of consecutive patients hospitalized with ASUC meeting Truelove and Witts' criteria from January 2015 to December 2020, across 14 hospitals in 4 Asian countries and 9 ANZ hospitals. RESULTS: A total of 861 patients were included, with 430 from Asia and 431 from ANZ. Baseline characteristics in the Asian and ANZ cohorts differed significantly, most notably with the Asian cohort having a lower proportion with an IBD family history (P < .001), more extensive disease at diagnosis (P < .001), and worse endoscopic severity (P < .001). At admission, significantly less Asian patients were currently taking corticosteroids, thiopurines, and biologics, and less had previous exposure to biologics (P < .005). More Asian patients were discharged on 5-aminosalicylates (P = .014), and fewer were prescribed corticosteroids (P = .049), thiopurines (P < .001), or advanced therapies (P < .001) on discharge, but more remained corticosteroid-dependent on follow-up (P < .029). The Asian cohort had lower rates of corticosteroid failure (21.5% vs 57.2%; P < .001), inpatient colectomy (2.8% vs 10.9%; P < .001), 1-year colectomy (4.7% vs 22.5%; P < .001), and readmission with ASUC within 12 months (9.3% vs 16.1%; P < .001), validated using a propensity score matched cohort. CONCLUSIONS: The characteristics of patients with ASUC in Asia differ significantly from ANZ. Despite worse endoscopic severity and more extensive disease, the Asian ASUC cohort appears more corticosteroid-responsive with significantly lower colectomy rates and less requirement for advanced therapies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fernandes RG, Kim DH, Ruddick-Collins L, et al. Acute Severe Ulcerative Colitis Patients From Asia Have Lower Colectomy Risk Than Patients From Australasia. Clin Gastroenterol Hepatol. 2025. PMID: 41173380. doi:10.1016/j.cgh.2025.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。